Fate Therapeutics Inc. (F6T)
XSTU 
Summary
F6T Chart
Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive
Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on FT819 for lupus nephritis. I believe FT819 has made good progress since the last time I covered the stock. They've reported broader autoimmune data and are now planning RECLAIM-LN. Unfortunately, I think their recent removal from the Russell 3000 index could be a near-term headwind for the stock price itself.
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.32 per share a year ago.
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.31 per share a year ago.
Fate Therapeutics Inc. (F6T) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fate Therapeutics Inc. ever had a stock split?
Fate Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Bahram Valamehr CEO | XSTU Exchange | 31189P102 CUSIP |
| US Country | 161 Employees | - Last Dividend | - Last Split | 1 Oct 2013 IPO Date |
Overview
Fate Therapeutics, Inc. stands at the forefront of the clinical-stage biopharmaceutical industry, with a clear focus on the crafting of programmed cellular immunotherapies designed to combat cancer and immune disorders on a global scale. With its foundation laid in 2007, the company has set its headquarters in San Diego, California, showcasing a steadfast commitment towards the development of innovative treatment solutions. Through a strategic collaboration and option agreement with Ono Pharmaceutical Co. Ltd., Fate Therapeutics aims to push the boundaries of medical advancements by spearheading the development and commercialization of off-the-shelf, induced pluripotent stem cell (iPSC)-derived CAR T-cell product candidates targeting a myriad of cancer types.
Products and Services
- FT576: Aimed at addressing the challenges presented by multiple myeloma, FT576 is a cutting-edge chimeric antigen receptor (CAR)-targeted natural killer (NK) cell product candidate. Its design and development epitomize Fate Therapeutics’ commitment to leveraging cellular immunotherapy for the treatment of complex cancers.
- FT522: As part of the company's robust portfolio, FT522 serves a dual purpose by targeting both lymphoma and autoimmune disorders. This CAR-targeted NK cell product candidate exemplifies the versatility and potential of cellular immunotherapy in treating a wide array of diseases beyond cancer, marking a significant stride towards comprehensive immunological treatments.
- FT819: Catering to the vast domain of hematologic malignancies and solid tumors, FT819 represents Fate Therapeutics’ foray into CAR T-cell programs. This initiative underscores the company’s dedication to expanding its therapeutic reach, employing genetically engineered T-cells to seek and destroy cancer cells, thereby offering a beacon of hope for patients grappling with various forms of cancer.
- FT825: Targeting solid tumors, FT825 further solidifies Fate Therapeutics’ foothold in the realm of CAR T-cell therapy. It showcases the company’s ongoing efforts to diversify its arsenal of immunotherapeutics, aiming to provide effective treatment options for patients battling with the relentless nature of solid tumors.
